Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLENA Regimen in Unresectable Pancreatic or Biliary Tract Cancer
NCT05327582Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, lenvatinib, paclitaxel in pancreatic cancer (PC), biliary tract cancer (BTC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
durvalumablenvatinibpaclitaxel
03
Conditions
pancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05327582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327582.